0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CLEC12A

CLEC12A

Brief Information

Name:C-Type lectin domain family 12 member A
Target Synonym:MICL,CD371,CLEC12A,DCAL2,DCAL-2,Dendritic cell-associated lectin 2,C-Type Lectin Domain Family 12 Member A,Myeloid Inhibitory C-Type Lectin-Like Receptor,CLL-1,CLL1,C-Type Lectin Domain Family 12, Member A,C-Type Lectin-Like Molecule-1,C-Type Lectin Prote
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

CLA-HP2Q3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CLA-H82F7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-CLEC12A CAR-293 were stained with 100 μL of 3 μg/mL of Biotinylated Human CLEC12A, Fc,Avitag (Cat. No. CLA-H82F7) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

CLA-H82E6-ELISA
Biotinylated Human CLEC12A, His,AvitagBiotinylated Human CLEC12A, His,Avitag (Cat. No. CLA-H82E6) ELISA bioactivity

Immobilized Biotinylated Human CLEC12A, His,Avitag (Cat. No. CLA-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).

CLA-H5266-MALS-HPLC
Human CLEC12A, Fc Tag (Cat. No. ) MALS images

The purity of Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) was more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human CLEC12A, Fc TagHuman CLEC12A, Fc Tag (Cat. No. CLA-H5266) ELISA bioactivity

Immobilized Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Synonym Name

CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371

Background

CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years.  The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Leukemia, Myeloid, Acute Details
ICG-136 ICG-136 Phase 1 Clinical Icell Gene Therapeutics Leukemia, Myeloid, Acute Details
CLL-1.CAR T cell therapy (Baylor College of Medicine) Phase 1 Clinical Baylor College Of Medicine Leukemia, Myeloid, Acute Details
Anti-CD33/CLL-1 CAR-T (Legend) Phase 1 Clinical Leukemia, Promyelocytic, Acute Details
Tepoditamab MCLA-117 Phase 1 Clinical Pharmaceutical Research Associates, Merus, Vu University Medical Center, Lgc, Institute Gustave-Roussy Leukemia, Myeloid, Acute Details
CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL1-CD33-cCAR Phase 1 Clinical Icell Gene Therapeutics, Chengdu Military General Hospital Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti-CLL1 CAR T cell therapy (The First Affiliated Hospital of Soochow University) Phase 2 Clinical Leukemia, Myeloid, Acute Details
KITE-222 Phase 1 Clinical Kite Pharma Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop